Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0174

Advisory board · Dr. Liam Eriksen

02 Mar 2026 · In person · Dr. Liam Eriksen, Peter MacCallum Cancer Centre · MSL Luis Ortega · Lumeva

ReviewedManualENG-0174—

Capture insight from this engagement

Location: Peter MacCallum Cancer Centre
Therapeutic area: Neurology
Country: Australia
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: LOLuis OrtegaMSL, Neurology (Iberia)
Product: Lumeva (lumevarin)

Topics discussed

Drug interactions

Scientific content used

CGRP class review

Questions raised

Any data in patients with medication-overuse headache?
Is there guidance on switching from a monoclonal antibody?

Notes

Advisory board with headache specialist at Peter MacCallum Cancer Centre. Discussed drug interactions.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Share MI standard response

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 2
Depth of exchange: 1
Actionability: 2

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0174

Audit history (0)

All create, update and approval events for this record

No audit events in sample data